This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall
by Zacks Equity Research
Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use
by Zacks Equity Research
Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Pfizer's (PFE) New Products May Drive Long-Term Sales Growth
by Kinjel Shah
Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.
Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump
by Zacks Equity Research
Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.
Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.
Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View
by Zacks Equity Research
Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.
Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day.
Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA Nod
by Zacks Equity Research
The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.
Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls
by Zacks Equity Research
Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.
Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio
by Zacks Equity Research
Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.
Do Options Traders Know Something About BioNTech (BNTX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.
Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab
by Zacks Equity Research
Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.
Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine
by Zacks Equity Research
Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.
FDA Approves Pfizer & Moderna's New COVID Booster Vaccines
by Kinjel Shah
Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.
Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant
by Zacks Equity Research
Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.
Novavax (NVAX) Stock Increases 9% in a Month: Here's Why
by Zacks Equity Research
This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.
Pfizer (PFE) & BioNTech Get CHMP Nod for Updated Covid-19 Jab
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech receive a positive recommendation from the CHMP for its Omicron XBB.1.5-adapted Covid-19 vaccine.
Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
In studies on small animals and primates, Novavax's (NVAX) updated monovalent COVID-19 vaccine generates a robust immune response against the currently dominating Eris variant.
The Zacks Analyst Blog Highlights Moderna, BioNTech, Novavax and Pfizer
by Zacks Equity Research
Moderna, BioNTech, Novavax and Pfizer are included in this Analyst Blog.
U.S. Govt to Urge Citizens to Get New COVID-19 Shots
by Zacks Equity Research
Shares of COVID-19 vaccine makers soared after reports suggest that the Biden administration will start a campaign urging citizens to vaccinate themselves with updated shots vaccine in the upcoming fall.
Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant
by Zacks Equity Research
Moderna's (MRNA) updated monovalent COVID-19 vaccine generates a robust immune response against the dominating Eris variant and another rapidly spreading virus strain in a clinical study.